Pramoxine hydrochloride

CAS No. 637-58-1

Pramoxine hydrochloride( —— )

Catalog No. M15419 CAS No. 637-58-1

Pramocaine hydrochloride is a topical anesthetic, and used as an antipruritic.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 37 In Stock
1G 43 In Stock

Biological Information

  • Product Name
    Pramoxine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Pramocaine hydrochloride is a topical anesthetic, and used as an antipruritic.
  • Description
    Pramocaine hydrochloride is a topical anesthetic, and used as an antipruritic.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Sodium Channel
  • Recptor
    Sodium Channel
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    637-58-1
  • Formula Weight
    329.86
  • Molecular Formula
    C17H27NO3·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 66 mg/mL (200.08 mM); Water: 66 mg/mL (200.08 mM); DMSO: 66 mg/mL (200.08 mM)
  • SMILES
    Cl.CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ramadan NK, Merey HA. Acta Chim Slov. 2012 Dec; 59(4):870-8.
molnova catalog
related products
  • APETx2

    Acid-sensing ion channel 3 (ASIC3) channel blocker (IC50 values are 63 and 175 nM for homomeric rat and human ASIC3 channels). Also inhibits NaV1.8 and NaV1.2 channels (IC50 values are 55 and 114 nM respectively). Demonstrates analgesic properties against acid-induced and inflammatory pain.

  • Bupivacaine

    Bupivacaine (AH-250) is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.

  • Aneratrigine hydroch...

    Aneratrigine hydrochloride is a sodium channel protein type 9 subunit blocker that may be used for the prevention or treatment of sodium channel blocker-related diseases.